ARCHIVES

NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner.

This article is from The Cancer Letter archive.

Vol. 32 No. 21 | June 2, 2006

Download PDF Visit The Full Archive

Related Articles

Cooperative Groups: PCPT Enrollment Complete, Three Years To The Day rial Began

December 13, 1996

Politics May Play Role In FDA’s Avastin Decision

May 27, 2011

DeVita Suggest “Overlay Consortium” as Outreach Mechanism for Southern California, Other Areas

September 28, 1984

Funding opportunities listed.

July 23, 2004

Letters From Ovarian Cancer Survivors Shed Light On Their Psychological Distress

October 31, 2003

NCI Begins Phase III Trial Of Shark Cartilage In NSCLC.

May 25, 2001